4//SEC Filing
Grigoriadis Dimitri E. 4
Accession 0001209191-21-009119
CIK 0000914475other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 9:18 PM ET
Size
18.3 KB
Accession
0001209191-21-009119
Insider Transaction Report
Form 4
Grigoriadis Dimitri E.
Vice President, Research
Transactions
- Sale
Common Stock
2021-02-05$113.76/sh−605$68,823→ 82,169 total - Award
Restricted Stock Unit
2021-02-08+6,376→ 6,376 total→ Common Stock (6,376 underlying) - Award
Stock Option
2021-02-08+38,256→ 38,256 totalExercise: $117.63Exp: 2031-02-08→ Common Stock (38,256 underlying) - Sale
Common Stock
2021-02-08$116.70/sh−1,218$142,142→ 85,273 total - Sale
Common Stock
2021-02-08$116.67/sh−687$80,152→ 83,456 total - Sale
Common Stock
2021-02-08$116.69/sh−803$93,705→ 84,178 total
Footnotes (11)
- [F1]Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F10]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F11]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.81 to $116.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Sale of 687 shares of common stock issued upon vesting of 1,974 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,287) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above.
- [F4]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Sale of 803 shares of common stock issued upon vesting of 1,525 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (722) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F6]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]Sale of 1,218 shares of common stock issued upon vesting of 2,313 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,095) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F8]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F9]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001423838
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 9:18 PM ET
- Size
- 18.3 KB